Meeting
2020 ASCO Virtual Scientific Program
Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL).
Authors
Martin H. Dreyling
University Hospital Groβhadern, Ludwig Maximilians-University, Munich, Germany
Martin H. Dreyling , Constantine Si Lun Tam , Michael Wang , Stephen Douglas Smith , Marco Ladetto , Huiqiang Huang , Rebecca L. Elstrom , Melannie Co , Eric Holmgren , Jane Huang , Steven Le Gouill
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04002297
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS8071)
DOI
10.1200/JCO.2020.38.15_suppl.TPS8071
Abstract #
TPS8071
Poster Bd #
404
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma.
First Author: Michael Wang
Poster
2023 ASCO Annual Meeting
BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
First Author: George Follows
Poster
2013 ASCO Annual Meeting
A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL).
First Author: Michael Wang
Poster
2023 ASCO Annual Meeting
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.
First Author: Loretta J. Nastoupil